UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
JANUARY 8, 2008
Date of Report (Date of earliest event reported)
MIV THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-30453 | 91-0809204 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Unit 1, 8765 Ash Street, Vancouver, British Columbia, Canada | V6P 6T3 | |
(Address of principal executive offices) | (Zip Code) |
(604) 301-9545
Registrant's telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
__________
TABLE OF CONTENTS
Item | Description |
5.01 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
__________
- 2 -
SECTION 2 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective January 8, 2008, Alan P. Lindsay resigned as Chief Executive Officer of MIV Therapeutics, Inc. (the "Company") and Dr. Mark Landy, the President of the Company, was appointed as Chief Executive Officer. Mr. Lindsay will remain Chairman of the Board of Directors of the Company.
Dr. Landy, age 39, had been MIV's President since April 1, 2006. Dr. Landy is also a director of the Company. Dr. Landy's mission is to strengthen and accelerate the Company's internal procedures and move its technologies to market. He is a recognized medical device analyst and industry authority who brings a wealth of industry and physician relationships to the Company that will be used to raise the Company's corporate profile, to optimize and accelerate the development of the Company's key strategic partnerships and to assist the Company in bringing to market its technologies.
Dr. Landy most recently distinguished himself as the Senior Research Analyst of Medical Supplies and Devices at the Susquehanna Research Group where he was voted the firm's top-ranked healthcare analyst by institutional clients in both 2004 and 2005. He is a familiar financial pundit who has made frequent appearances on CNBC, Reuters, Dow Jones, Bloomberg, The Wall Street Journal and Business Week, among other outlets. From 2001 to 2004, Dr. Landy was the Senior Medical Devise Analyst at Leerink Swann and Company.
Dr. Landy holds a degree in business from the Wharton School of Business at the University of Pennsylvania, and also holds the degree equivalent of Doctor of Dental Surgery from the University of Witwatersrand, in Johannesburg, South Africa. He spent three years in London, U.K., in private practice focusing on post-traumatic facial reconstructive surgery, and he has had articles published in both business and health care journals.
There are no family relationships among our directors or officers.
The Company paid or accrued management and consulting fees of $75,000, $285,600 and $38,000 to Dr. Landy in the three month period ended August 31, 2007, the year ended May 31, 2007 and the year ended May 31, 2006, respectively.
__________
- 3 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MIV THERAPEUTICS, INC. | |
|
|
__________
- 4 -